Dana Whittemore1, Lili Ding1,2, Lea E Widdice1,2, Darron A Brown3, David I Bernstein1,2, Eduardo L Franco4, Jessica A Kahn1,2. 1. 1 University of Cincinnati College of Medicine , Cincinnati, Ohio. 2. 2 Department of Pediatrics, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio. 3. 3 Department of Medicine, Indiana University , Indianapolis, Indiana. 4. 4 Departments of Oncology and Epidemiology and Biotatistics, McGill University , Montreal, Canada .
Abstract
BACKGROUND: Previous studies have demonstrated racial and ethnic differences in the distribution of human papillomavirus (HPV) types among adult women with cervical precancers. The aim of this study was to determine whether the distribution of vaccine-targeted HPV types varies by race/ethnicity among unvaccinated young women. MATERIALS AND METHODS: A secondary analysis was performed using data from four studies of sexually experienced, unvaccinated, 13-26-year-old women. Participants completed surveys and provided a cervicovaginal swab for HPV DNA testing. Multivariable logistic regression analyses were performed to examine whether race, ethnicity, and other factors were associated with type-specific HPV infection among the overall sample and among HPV-infected participants. Models controlled for age, HPV knowledge, sexual behaviors, substance use, and random study effect. RESULTS: The mean age of participants (N = 841) was 19.3 years; 64.4% were black and 8.9% Hispanic. Black women were more likely than white women to be positive for ≥1 HPV type (odds ratio [OR] 1.83, 95% CI 1.30-2.58) and Hispanic women were less likely than non-Hispanic women to be positive for ≥1 HPV type (OR 0.47, 95% CI 0.24-0.92). However, among all young women and HPV-infected women, neither race nor ethnicity was associated with positivity for HPV types targeted by the following vaccines: 2-valent (HPV16 and/or 18), 4-valent (HPV6, 11, 16, and/or 18), or 9-valent (HPV6, 11, 16, 18, 31, 33, 45, 52, and/or 58). CONCLUSION: The prevalence of HPV types targeted by the 2-valent, 4-valent, and 9-valent vaccines did not differ by race or ethnicity among all and among HPV-infected women in this sample.
BACKGROUND: Previous studies have demonstrated racial and ethnic differences in the distribution of human papillomavirus (HPV) types among adult women with cervical precancers. The aim of this study was to determine whether the distribution of vaccine-targeted HPV types varies by race/ethnicity among unvaccinated young women. MATERIALS AND METHODS: A secondary analysis was performed using data from four studies of sexually experienced, unvaccinated, 13-26-year-old women. Participants completed surveys and provided a cervicovaginal swab for HPV DNA testing. Multivariable logistic regression analyses were performed to examine whether race, ethnicity, and other factors were associated with type-specific HPV infection among the overall sample and among HPV-infectedparticipants. Models controlled for age, HPV knowledge, sexual behaviors, substance use, and random study effect. RESULTS: The mean age of participants (N = 841) was 19.3 years; 64.4% were black and 8.9% Hispanic. Black women were more likely than white women to be positive for ≥1 HPV type (odds ratio [OR] 1.83, 95% CI 1.30-2.58) and Hispanic women were less likely than non-Hispanic women to be positive for ≥1 HPV type (OR 0.47, 95% CI 0.24-0.92). However, among all young women and HPV-infectedwomen, neither race nor ethnicity was associated with positivity for HPV types targeted by the following vaccines: 2-valent (HPV16 and/or 18), 4-valent (HPV6, 11, 16, and/or 18), or 9-valent (HPV6, 11, 16, 18, 31, 33, 45, 52, and/or 58). CONCLUSION: The prevalence of HPV types targeted by the 2-valent, 4-valent, and 9-valent vaccines did not differ by race or ethnicity among all and among HPV-infectedwomen in this sample.
Entities:
Keywords:
epidemiology; ethnicity; human papillomavirus; race; vaccine
Authors: Jessica A Kahn; Darron R Brown; Lili Ding; Lea E Widdice; Marcia L Shew; Susan Glynn; David I Bernstein Journal: Pediatrics Date: 2012-07-09 Impact factor: 7.124
Authors: Tasneem Shikary; David I Bernstein; Yan Jin; Gregory D Zimet; Susan L Rosenthal; Jessica A Kahn Journal: J Clin Virol Date: 2009-08-08 Impact factor: 3.168
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Niti R Mehta; Pamela J Julian; James I Meek; Lynn E Sosa; Alyssa Bilinski; Susan Hariri; Lauri E Markowitz; James L Hadler; Linda M Niccolai Journal: Obstet Gynecol Date: 2012-03 Impact factor: 7.661
Authors: Lavinia Lin; Vicki B Benard; April Greek; Nikki A Hawkins; Katherine B Roland; Mona Saraiya Journal: Prev Med Date: 2015-09-09 Impact factor: 4.018
Authors: Nicolas Van de Velde; Marie-Claude Boily; Mélanie Drolet; Eduardo L Franco; Marie-Hélène Mayrand; Erich V Kliewer; François Coutlée; Jean-François Laprise; Talía Malagón; Marc Brisson Journal: J Natl Cancer Inst Date: 2012-10-27 Impact factor: 13.506
Authors: Linda M Niccolai; Chelsea Russ; Pamela J Julian; Susan Hariri; John Sinard; James I Meek; Vanessa McBride; Lauri E Markowitz; Elizabeth R Unger; James L Hadler; Lynn E Sosa Journal: Cancer Date: 2013-05-09 Impact factor: 6.860
Authors: Jacqueline Hirth; Christine J McGrath; Yong-Fang Kuo; Richard E Rupp; Jonathan M Starkey; Abbey B Berenson Journal: Vaccine Date: 2018-10-28 Impact factor: 3.641
Authors: Marla J Keller; Robert D Burk; L Stewart Massad; Isam-Eldin Eltoum; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Laura L Reimers; Mark Kuniholm; Gypsyamber DʼSouza; Christine Colie; Bradley Aouizerat; Joel M Palefsky; Howard D Strickler Journal: AIDS Date: 2018-11-28 Impact factor: 4.632